Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2013


#173804

84pages

Global Markets Direct

$ 2000

In Stock

 

Global Markets Directs, 'Hematopoietic Stem Cell Transplantation Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation. Hematopoietic Stem Cell Transplantation Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

  • A snapshot of the global therapeutic scenario for Hematopoietic Stem Cell Transplantation.
  • A review of the Hematopoietic Stem Cell Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Hematopoietic Stem Cell Transplantation pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

  • Identify and understand important and diverse types of therapeutics under development for Hematopoietic Stem Cell Transplantation.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Hematopoietic Stem Cell Transplantation pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents


Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hematopoietic Stem Cell Transplantation Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Hematopoietic Stem Cell Transplantation 8
Hematopoietic Stem Cell Transplantation Therapeutics under Development by Companies 10
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Hematopoietic Stem Cell Transplantation Therapeutics - Products under Development by Companies 15
Companies Involved in Hematopoietic Stem Cell Transplantation Therapeutics Development 16
Hospira, Inc. 16
Athersys, Inc. 17
GlaxoSmithKline plc 18
BioLineRx, Ltd. 19
Celldex Therapeutics, Inc. 20
Antisense Therapeutics Limited 21
Actinium Pharmaceuticals, Inc. 22
Pharmalink AB 23
Polyphor Ltd. 24
Kiadis Pharma B.V. 25
Bellicum Pharmaceuticals, Inc. 26
TaiGen Biotechnology Co., Ltd. 27
TikoMed AB 28
Hematopoietic Stem Cell Transplantation - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
ronacaleret hydrochloride - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
MultiStem - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
busulfan liposomal IR - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ATIR - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
POL-6326 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CDX-301 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ATL-1102 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
TXA-127 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
burixafor - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
filgrastim - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
PanCyte - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
BL-8040 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
BL-8040 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Iomab-B - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Hematopoietic Stem Cell Transplantation Therapeutics - Drug Profile Updates 58
Hematopoietic Stem Cell Transplantation Therapeutics - Discontinued Products 73
Hematopoietic Stem Cell Transplantation Therapeutics - Dormant Products 74
Hematopoietic Stem Cell Transplantation - Product Development Milestones 75
Featured News & Press Releases 75
Jul 09, 2013: MultiStem Cell Therapy May Overcome Major Challenges in Organ Transplantations 75
May 07, 2013: Pluristem Develops PLX-RAD Cells For Use In Hematology 76
Mar 28, 2013: Chimerix Announces Presentation Of Data On Antiviral Compound CMX001 At EBMT Annual Meeting 77
Mar 22, 2013: Gentium Receives Negative Opinion From CHMP On Defibrotide For Treatment And Prevention Of VOD 78
Feb 14, 2013: Celldex Announces Positive Data From Phase I Study Of CDX-301 Support Initiation Of Pilot Study In Hematopoietic Stem Cell Transplantation 78
Feb 11, 2013: Celldex Therapeutics Announces Upcoming Oral Presentation On CDX-301 At American Society For Blood And Marrow Transplantation 2013 BMT Tandem Meetings 79
Feb 04, 2013: Chimerix To Present Three Abstracts Related To Antiviral CMX001 At BMT Tandem Meetings 79
Feb 04, 2013: Gamida Cells StemEx Achieves Primary Endpoint In Phase II/III Clinical Study 80
Dec 13, 2012: Gentium Announces Presentation Of Additional Data From Ongoing Trials Of Defibrotide At American Society Of Hematology Annual Meeting 80
Dec 11, 2012: Celldex Therapeuticss CDX-301 Safely Mobilizes Hematopoietic Cells In Phase I Study 82


Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 84
Disclaimer 84


Number of Products Under Development for Hematopoietic Stem Cell Transplantation, H2 2013 8
Products under Development for Hematopoietic Stem Cell Transplantation - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 11
Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
Comparative Analysis by Early Clinical Stage Development, H2 2013 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 14
Products under Development by Companies, H2 2013 15
Hospira, Inc., H2 2013 16
Athersys, Inc., H2 2013 17
GlaxoSmithKline plc, H2 2013 18
BioLineRx, Ltd., H2 2013 19
Celldex Therapeutics, Inc., H2 2013 20
Antisense Therapeutics Limited, H2 2013 21
Actinium Pharmaceuticals, Inc., H2 2013 22
Pharmalink AB, H2 2013 23
Polyphor Ltd., H2 2013 24
Kiadis Pharma B.V., H2 2013 25
Bellicum Pharmaceuticals, Inc., H2 2013 26
TaiGen Biotechnology Co., Ltd., H2 2013 27
TikoMed AB, H2 2013 28
Assessment by Monotherapy Products, H2 2013 29
Assessment by Stage and Route of Administration, H2 2013 31
Assessment by Stage and Molecule Type, H2 2013 33
Hematopoietic Stem Cell Transplantation Therapeutics - Drug Profile Updates 58
Hematopoietic Stem Cell Transplantation Therapeutics - Discontinued Products 73
Hematopoietic Stem Cell Transplantation Therapeutics - Dormant Products 74


Number of Products under Development for Hematopoietic Stem Cell Transplantation, H2 2013 8
Products under Development for Hematopoietic Stem Cell Transplantation - Comparative Analysis, H2 2013 9
Products under Development by Companies, H2 2013 10
Mid Clinical Stage Products, H2 2013 12
Early Clinical Stage Products, H2 2013 13
Pre-Clinical Stage Products, H2 2013 14
Assessment by Monotherapy Products, H2 2013 29
Assessment by Route of Administration, H2 2013 30
Assessment by Stage and Route of Administration, H2 2013 31
Assessment by Molecule Type, H2 2013 32
Assessment by Stage and Molecule Type, H2 2013 33